T. Rowe Price Associates’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
|
|||||
|
2024
Q1 | $18K | Buy |
|
|||||
|
2023
Q4 | $9K | Sell |
|
|||||
|
2023
Q3 | $48K | Sell |
|
|||||
|
2023
Q2 | $122K | Hold |
|
|||||
|
2023
Q1 | $192K | Buy |
|
|||||
|
2022
Q4 | $202K | Buy |
|
|||||
|
2022
Q3 | $445K | Buy |
|
|||||
|
2022
Q2 | $262K | Buy |
|
|||||
|
2022
Q1 | $290K | Buy |
|
|||||
|
2021
Q4 | $323K | Sell |
|
|||||
|
2021
Q3 | $8.09M | Sell |
|
|||||
|
2021
Q2 | $8.56M | Buy |
|
|||||
|
2021
Q1 | $11M | Buy |
|